GlassScriptPhysician profile
James R Fox
NPI 1730115718
$5,276.49
in general payments reported to CMS, 2019-2025
40 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $774 · 2022: $1,011 · 2023: $970 · 2024: $1,175 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,491.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $928.24 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $642.57 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $618.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $450.60 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $415.79 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $222.60 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.35 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $169.76 | 2021-2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $103.82 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $103.01 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $94.00 | 2021-2023 | Epclusa |
| Amgen INC. | $87.97 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Phathom Pharmaceuticals, INC. | $84.43 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.35 | 2021-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $77.63 | 2021-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.07 | 2023-2025 | Caplyta |
| Corcept Therapeutics | $72.69 | 2024-2025 | Korlym |
| Inari Medical, INC. | $71.51 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $65.28 | 2023 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $54.92 | 2021 | |
| Astellas Pharma US INC | $52.66 | 2022-2025 | Veozah |
| Ironwood Pharmaceuticals, INC | $51.21 | 2021-2022 | |
| Shield Therapeutics INC | $47.58 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.17 | 2022 | |
| Abbott Laboratories | $45.11 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $44.33 | 2021-2022 | |
| Lundbeck LLC | $38.10 | 2022-2025 | Rexulti |
| Organon LLC | $37.17 | 2022-2023 | Nexplanon |
| Ani Pharmaceuticals, INC. | $30.47 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $30.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.35 | 2021-2022 | |
| Amarin Pharma, INC. | $28.18 | 2021 | |
| Dynavax Technologies Corporation | $27.13 | 2024 | Heplisav-B |
| Eisai INC. | $26.55 | 2021 | |
| Merck Sharp & Dohme LLC | $24.75 | 2021 | |
| Tandem Diabetes Care, INC. | $24.60 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pacira Pharmaceuticals Incorporated | $18.59 | 2024 | Zilretta, Iovera, Exparel |
| Daiichi Sankyo INC. | $15.37 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.05 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.